Cross-Border Healthcare Intelligence
An enterprise-grade clinical intelligence platform that shatters the medical data wall between Chinese patients and elite Western specialists. Built on verified data provenance, longitudinal synthesis, and integrated Eastern-Western medicine.
The Problem
For high-income Chinese patients and expatriates seeking care at elite Western institutions, the barrier is not money, language, or geography. It is data format.
Top-tier specialists at Mayo Clinic, MD Anderson, Johns Hopkins, and equivalent institutions will not review raw, translated PDFs. They demand organized, standardized, longitudinal medical histories before accepting a case. The patient has the money. The specialist has the capacity. The data wall makes the transaction impossible.
This is not a cultural or communication problem. It is a data engineering problem. And data engineering problems have solutions.
The Solution
An enterprise-grade medical data engine. Zero-defect processing pipeline. Every clinical marker extracted, standardized, and synthesized into the exact format the receiving specialist requires.
Ingests records from Chinese patient portals, hospital exports, and scanned documents in any format. Extracts CBC trends, HbA1c, lipid panels, vital signs, medication histories, diagnoses, and procedures. Zero data loss. Every extracted marker linked to its source document.
Compiles records from every institution the patient visited into a single verified chronological narrative. Isolates overlapping conditions. Surfaces diagnostic gaps. Maps TCM and Western medicine findings into a unified timeline. A 20-year history becomes comprehensible in a 15-minute visit.
Output formatted to the exact intake requirements of the target institution — Mayo Clinic, Johns Hopkins, MD Anderson, or any specified specialist center. English narrative. US-standard units. Western formulary drug names. FHIR R4-compliant data export. 3D clinical visualization blueprints.
The only platform that holds Traditional Chinese Medicine diagnostic records and Western clinical data in the same longitudinal timeline — neither system overwriting the other. A patient's syndrome differentiation history and their hemoglobin A1c trend appear in the same chronological view. This is not a feature. It is a fundamental architectural commitment to the reality of how high-income Chinese patients manage their health.
Target Markets
Each segment has high friction, low current technology adoption, and demonstrated willingness to pay for a system that works.
Upper-income patients in Beijing, Shanghai, and Shenzhen. Self-pay for international consultation. Price-insensitive when health is the subject. Existing relationships with international travel medicine providers and private concierge health services.
Fortune 500 and Chinese state enterprise employees on international assignment. The employer is the buyer, not the individual. High volume, predictable annual contract revenue. Health synthesis delivered as an employee benefit. Fastest path to signed revenue.
JCI-accredited hospitals in China with international intake programs. Medical tourism facilitator agencies. International hospitals deploying a branded intake pipeline. White-label licensing with per-case volume fee on top of annual license.
National-level institutions, diplomatic community, government officials, state enterprise headquarters. Strongest concentration of patients with access to international networks and willingness to pay for premium care.
Financial center. Largest expatriate population in China. Most internationalized healthcare market. Multiple JCI-accredited hospitals already operating. Primary corporate health buyer concentration.
Bridge between mainland China and international healthcare. Established Western medical infrastructure. Regional operations and data management center. Less restrictive regulatory environment for cross-border health data.
Revenue Model
Small per-case fees across high patient volume compounds quickly. The medical tourism market from China sends over 600,000 patients internationally per year. That is the total addressable market before corporate health subscriptions or institutional licensing.
Architecture Principles
Consumer-grade AI cannot handle Protected Health Information at scale. This platform is built on a rigid enterprise architecture designed to meet the strictest evidentiary and compliance standards. Four non-negotiable principles.
Strategic Vision
The objective is not to process records after illness occurs. It is to use longitudinal data to identify patterns that predict illness before it manifests. A patient whose TCM constitutional assessment and Western biomarkers show a converging trend toward a chronic condition needs to know before the crisis — not after.
High-income Chinese patients do not choose between TCM and Western medicine. They use both. A platform that forces them to translate between the two systems is a platform that loses half the clinical picture. This platform holds both frameworks simultaneously in a single longitudinal record.
The China market is the entry point. The architecture is designed to scale to every high-friction medical environment on earth — wherever patients with complex records need access to specialists who cannot decode them. The Medical Data Wall exists in every country. The solution is the same everywhere.
For Qualified Partners
Detailed technical architecture, proprietary data methodology, deployment specifications, revenue share terms, and pilot program structure are available to qualified investors, hospital systems, and corporate health partners under non-disclosure agreement.
Request Partner Access →